The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β

The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β

Transforming growth factor-β (TGF-β) plays a critical role in regulating cell growth and differentiation. Epithelial to mesenchymal transition (EMT) induced by TGF-β promotes cancer cell migration, invasion, and proliferation. Pirfenidone (5-methyl-1-phenyl-2(1 H)-pyridone, PFD), an approved drug fo...

Full description

Bibliographic Details
Main Authors: Gang Wang, Xiaowan Zhou, Zengli Guo, Nan Huang, Juan Li, Yanfang Lv, Lulu Han, Wei Zheng, Dandan Xu, Dafei Chai, Huizhong Li, Liantao Li, Junnian Zheng
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Cancer Biology & Therapy
Subjects:
pirfenidone
tgf-β
renal cell carcinoma
epithelial-to-mesenchymal transition
tumor microenvironment (tme)
myeloid-derived suppressor cells (mdsc)
Online Access:http://dx.doi.org/10.1080/15384047.2022.2035629

Similar Items

Similar Items